Skip to main content
Cash
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive168AccountSocial
MARKETSINVESTLIVE168
Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
Series Image
  1. Medicine

Will the FDA approve VERVE-102?



Chance

Before 2030
50%

Before 2030

50%

Before 2031
69%

Before 2031

69%

Before 2032
76%

Before 2032

76%

3 more

Will the FDA approve VERVE-102?

Before 2030

Odds
58% chance
Max payout
Dec 31, 2029
$0
$1,815 vol
More Science and Technology Markets

Trending Science and Technology markets

Best AI at the end of 2026?Will the U.S. confirm that aliens exist?DeepSeek market share this weekOpenAI market share this weekGoogle market share this weekWhen will OpenAI release Astra 6.1+?Anthropic market share this weekOpen vs. Closed Token Volume (open weights share) today

Science and Technology hub

All Science and Technology markets